Prescryptive Health Closes $26 Million Series A Financing

Digital health platform founded by former Microsoft cloud veterans is
redefining the U.S. prescription drug market

SEATTLE, August 25, 2020 – Seattle-based Prescryptive Health, a digital health company focused on improving the prescription drug market, announced the close of a $26 million Series A financing round. The round was led by Morningside Ventures and was joined by existing investors SeaChange Fund and Pallasite Ventures.  Morningside’s co-founder Dr. Gerald Chan has joined the company’s board.

Prescryptive launched the world’s first prescription intelligence platform powered by blockchain to democratize the prescription drug market, providing market participants access to unbiased information, pricing and choice. With Prescryptive’s platform, patients receive the necessary information they need when it matters most—at the point of care. For the first time, patients know what a prescribed treatment costs, how much their insurance will cover, their out-of-pocket expense, and what lower cost alternatives are available. Most importantly, this information is delivered in real-time to their mobile device while they are engaged with their healthcare provider.

Read more here.